All In Biotech

Drug Trial Radar · NCT03400800

Inclisiran for Subjects With ASCVD or ASCVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol

A Placebo-Controlled, Double-Blind, Randomized Trial to Evaluate the Effect of 300 mg of Inclisiran Sodium Given as Subcutaneous Injections in Subjects With Atherosclerotic Cardiovascular Disease (ASCVD) or ACSVD Risk-Equivalents and Elevated Low-Density Lipoprotein Cholesterol (LDL-C)

Last checked: Nov 19, 2026Latest source record: Aug 21, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,617 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,617

Actual

Start

Nov 1, 2017

Primary completion

Jul 31, 2019

Study completion Aug 27, 2019

Sponsor

Lead sponsor
The Medicines CompanyIndustry
Sponsor type
Industry
First posted
Jan 17, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, care provider)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase III, placebo-controlled, double-blind, randomized study in participants with ASCVD or ASCVD-Risk equivalents and elevated LDL-C despite maximum tolerated dose of LDL-C lowering therapies to evaluate the efficacy, safety, and tolerability of subcutaneous (SC) inclisiran injection(s). The study will be an international multicenter study (non-United States).

Conditions

  • ASCVD
  • Risk Factor, Cardiovascular
  • Elevated Cholesterol

Interventions

  • Inclisiran SodiumDrug

    Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.

  • PlaceboDrug

    Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage Change in LDL-C From Baseline to Day 510Time frame: Baseline, Day 510
  2. Time-adjusted Percent Change in LDL-C Levels From Baseline After Day 90 and up to Day 540Time frame: Baseline, Day 90 to Day 540

Locations

70 sites in 7 countries. Site status is shown where the registry gives one.

  • Research Site 11420-002

    Chomutov, Czechia

  • Research Site 11420-003

    Uherské Hradiště, Czechia

  • Research Site 11049-006

    Berlin, Germany

  • Research Site 11049-002

    Bochum, Germany

  • Research Site 11049-003

    Frankfurt, Germany

  • Research Site 11049-007

    Heidelberg, Germany

  • Research Site 11049-001

    Leipzig, Germany

  • Research Site 11036-001

    Budapest, Hungary

  • Research Site 11036-004

    Debrecen, Hungary

  • Research Site 11036-002

    Hatvan, Hungary

  • Research Site 11036-003

    Zalaegerszeg, Hungary

  • Research Site 11048-011

    Bydgoszcz, Poland

  • Research Site 11048-004

    Gdansk, Poland

  • Research Site 11048-017

    Gdansk, Poland

  • Research Site 11048-005

    Gdynia, Poland

  • Research Site 11048-007

    Katowice, Poland

  • Research Site 11048-012

    Katowice, Poland

  • Research Site 11048-014

    Krakow, Poland

  • Research Site 11048-003

    Krakow, Poland

  • Research Site 11048-008

    Lublin, Poland

  • Research Site 11048-001

    Poznan, Poland

  • Research Site 11048-013

    Rzeszów, Poland

  • Research Site 11048-015

    Tarnów, Poland

  • Research Site 11048-009

    Warsaw, Poland

  • Research Site 11048-006

    Warszawice, Poland

  • Research Site 11048-002

    Wroclaw, Poland

  • Research Site 11048-010

    Wroclaw, Poland

  • Research Site 11048-018

    Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland

  • Research Site 11048-016

    Brzozów, Podkarpackie Voivodeship, Poland

  • Research Site 11048-019

    Ruda Śląska, Silesian Voivodeship, Poland

  • Research Site 11027-006

    Pretoria, South Africa

  • Research Site 11027-011

    Welkom, South Africa

  • Research Site 11027-003

    Bloemfontein, Free State, South Africa

  • Research Site 11027-005

    Johannesburg, Gauteng, South Africa

  • Research Site 11027-001

    Cape Town, Western Cape, South Africa

  • Research Site 11027-013

    Cape Town, Western Cape, South Africa

  • Research Site 11027-007

    Kuils River, Western Cape, South Africa

  • Research Site 11027-004

    Somerset West, Western Cape, South Africa

  • Research Site - 11380-005

    Cherkasy, Ukraine

  • Research Site - 11380-008

    Kharkiv, Ukraine

Showing 40 of 70 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.